Kyphoscoliosis Treatment Global Market Report 2024

The kyphoscoliosis treatment market size has grown strongly in recent years. It will grow from $2.89 billion in 2023 to $3.08 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The increase observed in the historical period can be attributed to the exploration of regenerative medicine, contributions from genetic research, the adoption of telemedicine and remote monitoring, and advancements in rehabilitation programs.

The kyphoscoliosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.84 billion in 2028 at a compound annual growth rate (CAGR) of 5.7%. The anticipated growth in the forecast period can be attributed to personalized treatment approaches, the expansion of biomechanical research, the increased utilization of remote monitoring and telehealth services, and ongoing genetic research. Major trends expected in the forecast period involve advanced surgical techniques, the adoption of innovative bracing technologies, the development of customized treatment plans, the increased adoption of 3D printing in the medical field, and ongoing innovations in pain management.

The anticipated increase in spinal cord injuries is poised to drive the growth of the kyphoscoliosis treatment market. Spinal cord injuries encompass trauma or damage to various spine structures, leading to conditions such as kyphoscoliosis and impacting spinal alignment. Treatment for kyphoscoliosis linked with spinal cord injuries involves a comprehensive approach, including orthopedic evaluation, physical therapy, bracing, potential surgery, pain management, and a multidisciplinary healthcare team. Notably, there has been a rise in sporting and recreational spinal cord injuries, increasing from 14% in 2020 to 19% in 2021, as reported by the New Zealand Spinal Trust. This upward trend, influenced by activities such as mountain biking and cycling, underscores the driving force of the rising number of spinal cord injuries on the kyphoscoliosis treatment market.

The escalating use of telemedicine is expected to be a significant driver of growth in the kyphoscoliosis treatment market. Telemedicine, utilizing telecommunications technology for remote clinical services, facilitates remote consultations with orthopedic specialists and spine surgeons. This is particularly beneficial for individuals facing difficulties in traveling to healthcare facilities due to the physical limitations associated with kyphoscoliosis. The widespread utilization of telehealth, with 37% of individuals, including 42% of women, continuing to use it in 2021 according to the Centers for Disease Control and Prevention (CDC), is a key factor propelling the growth of the kyphoscoliosis treatment market.

The increasing incidence of genetic disorders is expected to be a significant catalyst for the growth of the kyphoscoliosis treatment market. Genetic disorders, stemming from abnormalities or mutations in an individual's DNA, often involve spinal curvature abnormalities requiring kyphoscoliosis treatment. The prevalence of genetic conditions in children is estimated to be 1 in 25 in the UK, affecting over 2.4 million individuals. The multidisciplinary treatment approach, encompassing various strategies such as beta-blocker therapy, physical therapy, and orthopedic surgeon supervision, underlines the pivotal role of kyphoscoliosis treatment in managing genetic disorders and contributes to market growth.

The high cost of treatment poses a challenge and may impede the market's growth during the forecast period. Surgical interventions, characterized by complexity and the need for specialized equipment and expertise, incur substantial costs. This financial burden can be particularly prohibitive in underdeveloped nations with limited healthcare resources. For instance, the average cost of revision surgery due to proximal junctional kyphosis (PJK) in adult spinal deformity patients was $93,688, significantly higher than $21,467. The high cost of treatment acts as a hindrance to the growth of the kyphoscoliosis treatment market.

Major companies in the kyphoscoliosis treatment market are focusing on innovative product development, exemplified by the MARVEL Growing Rod System designed for early-onset scoliosis. The MARVEL Growing Rod System, launched by Globus Medical Inc., is a posterior stabilizing rod that can be surgically implanted and periodically stretched, offering substantial diversion, immediate tactile feedback, and automated locking for dependable growth. This innovation, including cutting-edge items such as the Growing Rod System, is anticipated to contribute to the future expansion of the market.

Major companies operating in the kyphoscoliosis treatment market report are Johnson & Johnson Services Inc., Aspen Medical Products LLC, Medtronic plc, Stryker Corporation, Milwaukee Brace Company, Zimmer Biomet Holdings Inc., Perrigo Company plc, Teva Pharmaceuticals Inc., B. Braun Melsungen Aktiengesellschaft, Aurobindo Pharma Limited, Integra LifeSciences Ltd., NuVasive Inc., DJO Global Inc., Globus Medical Inc., Boston Orthotics & Prosthetics, Ossur hf., Aesculap Inc., DeRoyal Industries Inc., MicroPort Scientific Corp., Alphatec Holdings Inc., Trulife Ltd., Ottobock SE & Co. KGaA, Orthofix Holdings Inc., OrthoPediatrics Corp., Proteor S.A., Orthomerica Products Inc., Breg Inc., Innomed Inc., Restorative Care of America Inc., Spinal Elements Inc.

North America was the largest region in the kyphoscoliosis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kyphoscoliosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the kyphoscoliosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kyphoscoliosis treatment market consists of revenues earned by entities by providing services such as physical therapy, pain management, specialist psychological support, and medical evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The kyphoscoliosis treatment market also includes sales of lumbar support cushions, orthopedic braces, back support belts, and exercise and therapy equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main types of kyphoscoliosis include postural kyphosis, Scheuermann’s kyphosis, congenital kyphosis, and kyphoscoliosis. Postural kyphosis refers to the rounding or hunching of the back, typically affecting teenagers and young adults. Treatment options for kyphoscoliosis encompass medications, surgery, and bracing, and these are implemented by hospitals, clinics, and ambulatory surgical centers.

The kyphoscoliosis treatment market research report is one of a series of new reports that provides kyphoscoliosis treatment market statistics, including kyphoscoliosis treatment industry global market size, regional shares, competitors with a kyphoscoliosis treatment market share, detailed kyphoscoliosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kyphoscoliosis treatment industry. This kyphoscoliosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.